|
|
General
|
| |
Clinical Use:
|
Glutamic acid decarboxylase (GAD65) antibodies are found in approximately 75% of patients with type 1 diabetes. GAD65 antibodies may also be found in rare neurologic syndromes including stiff person syndrome, cerebellar ataxia and autoimmune epilepsy syndromes. Patients with neurologic syndromes associated with GAD65 antibodies typically have much higher GAD65 antibody levels compared to patients with type 1 diabetes.
Quantitation of GAD65 antibody levels is performed by ELISA on serum samples only and is not performed on CSF specimens. CSF samples can be tested qualitatively for the presence of GAD65 antibodies by indirect immunofluorescence (test panel PNIFC). This should be performed in parallel with a paired serum sample (test panel PNIFS). |
| |
Availability:
|
Serum testing is performed fortnightly.
PNIFC testing on CSF samples is performed weekly. |
| |
Aliases/Synonyms:
| Anti-GAD, Anti-Glutamic Acid Decarboxylase, Diabetes Autoantibody Assay (GAD), GAD, GAD 65, GAD 67, Glutamic Acid Decarboxylase Autoantibody, IDDM Auto Antibody, Stiff Person Syndrome, |
| |
Code:
|
Serum: GAD / CSF: PNIFC |
| |
Handling Instructions (to laboratory):
|
Send sample chilled. |
| |
Hyperlink:
|
|
| |
Reference Interval:
|
Refer to report or laboratory
|
Collection Requirements
|
| |
Container:
|
Serum Sep. Tube-SST (GOLD), or, CSF Tube 1 (CSF1), |
| |
Sample Type:
|
Serum (GAD); CSF (PNIFC) |
| |
Minimum Collection Volume:
|
|
| |
Collection Instructions:
|
|
Processing Requirements
|
| |
Alternate Containers:
|
|
| |
Processing Instructions:
|
If request is for 'Diabetes Antibodies' please add BOTH GAD and IA2 tests. |
| |
Minimum Assay Volume:
|
50uL |
| |
Stability:
|
|
| |
Transport Instructions (to testing laboratory):
|
Send sample chilled. |
Testing Locations
|
| |
Performed at:
|
|
Section
|
Department
|
Site
|
Contact Phone
|
| - |
Immunology |
QEII Medical Centre |
6383 4306 |
|
Last Updated : 30-05-2025 09:44 |